I will second that NOT allo you have never been right once in any of your statement. Not ONCE!!! But we should think this time it's going to happen. And I will be here until the end as well, willing and easily able to discount feeble attempts to justify this pathetic management and board.
Exactly with regards to no bad results. I told them to read the Edison report. Totally oblivious to it all. No comment at all. Just ignore. Here are some parts that were obviously ignored
To date, the company has not achieved any statistically significant results for an approvable endpoint in any of its programs.
We expect that the company will require $50m in additional capital, in addition to any development grants, to reach profitability in 2020. This value may increase dramatically if the company is unable to secure a procurement contract for PLX-R18 at that time
CLI... There is a high degree of variability for AFS reported in the literature, and the rate appears to have been increasing since the mid-1990s due to higher rates of revascularization procedures as well as better diabetes control, antiplatelet therapy, infection control and smoking cessation.
Hip trial...PLX-PAD has been studied in a single Phase I/II study in patients following elective THR, which reported results in January 2014. It should be noted that this indication is different to current hip injury indication and included patients that opted for THR as a treatment for osteoarthritis. These patients have a significantly higher quality of life and lower morbidity than patients following hip fracture.
